ストックスクリーナーアプリを入手
2.00
2.04%
0.04
プレマーケット:
2.01
0.010
+0.50%
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan
Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO) - The Globe and Mail
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 7.7%Here's What Happened - MarketBeat
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - The Globe and Mail
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
RBC Capital Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Transcript : Allogene Therapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 - marketscreener.com
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and Financial Strength - GuruFocus
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
ALLO Adjusts 2026 Operating Expense Guidance - GuruFocus
Allogene Therapeutics Q1 Earnings Call Highlights - MarketBeat
Allogene Therapeutics ends China cell therapy deal with Overland - 1470 & 100.3 WMBD
Allogene Therapeutics (NASDAQ: ALLO) Belldegrun reports 13.47M-share stake - Stock Titan
ALLO Secures Funding, Extends Cash Runway to 2029 - GuruFocus
Allogene (ALLO) Q1 2026 Earnings Transcript - The Globe and Mail
ALLO: Interim data show robust efficacy and safety for cema-cel and early promise for ALLO-329, with solid financials - TradingView
Allogene Therapeutics Q1 Net Loss Narrows - Moomoo
Allogene Therapeutics Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Allogene Therapeutics beats EPS expectations in Q1 2026 - Investing.com
Allogene Therapeutics releases Q1 corporate update with focus on allogeneic cell therapy progress - Traders Union
Allogene Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allogene Highlights ALPHA3 Data and Extended Cash Runway - TipRanks
Is Allogene Therapeutics (ALLO) Undervalued After Q1 2026? EPS - GuruFocus
Allogene Therapeutics (ALLO) insider holdings: Dr. Chang 4.9% ownership disclosed - Stock Titan
Allogene TherapeuticsEnters Termination Agreement With Overland Therapeutics On May 12, 2026SEC Filing - TradingView
Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss - marketscreener.com
Allogene Therapeutics: Q1 Earnings Snapshot - Barchart.com
Allogene (NASDAQ: ALLO) extends cash runway to 2029 as CAR T trials advance - Stock Titan
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allogene (NASDAQ: ALLO) posts Q1 2026 loss, updates ALPHA3 data and cash runway - Stock Titan
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire
More on Allogene Therapeutics - MSN
Allogene Therapeutics Q1 2026 earnings preview - MSN
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ... By GuruFocus - Investing.com Canada
MSN Money - MSN
Allogene Therapeutics to hold quarterly update on cell therapy progress - Traders Union
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):